About This Fund
Invivo Ventures AI is a EUR 100 million early-stage venture capital fund managed by Invivo Partners, S.G.E.I.C, S.A., a Barcelona-based CNMV-registered fund manager with over EUR 150 million in assets under management. Announced in September 2025, the fund represents the fourth vehicle in Invivo Partners' franchise and marks a strategic evolution toward the intersection of artificial intelligence and scientific innovation — positioning itself as Spain's first locally focused vehicle dedicated exclusively to AI-driven science. The hard cap is set at EUR 120 million, with first close expected in H1 2026. The fund was established alongside the appointment of Dr. Josep M. (Pep) Martorell as Partner, who led innovation at the Barcelona Supercomputing Center and helped create programmes resulting in 14 spin-offs raising over EUR 40 million. The broader Invivo Partners platform has historically received institutional support from the European Investment Fund (EIF), Fond-ICO, the Institut Catala de Finances, and Barcelona City Council.
The fund's investment thesis holds that artificial intelligence is now foundational infrastructure for any deeptech company. Accordingly, Invivo Ventures AI targets pre-seed through Series A companies applying AI to advance biotechnology, life sciences, synthetic biology, robotics, aerospace, mobility, computing and climate technology. Healthcare and life sciences constitute more than 50% of the intended portfolio. Initial ticket sizes range from EUR 2 million to EUR 4 million per investment, with follow-on reserves of up to EUR 10 million per company post-milestone. The geographic mandate is primarily Spanish-headquartered or Spanish-originated startups, with broader European coverage for the most compelling AI-science opportunities.
Invivo Partners has built a track record through three prior funds including Healthequity VC Fund (2012-2019), Invivo Ventures FCR (EUR 60 million final close, 2019), and Invivo Ventures III (EUR 100 million target, first close H1 2024). The firm is co-founded and led by Luis Pareras and Albert Ferrer, with Laura Rodriguez and Pep Martorell serving as partners. Barcelona's position as a leading European biomedical research hub — home to research institutions, hospitals and a growing deep-tech ecosystem — provides Invivo with privileged deal flow access, particularly in the AI-driven life sciences segment where the city's scientific institutions have produced a pipeline of commercially relevant spin-offs.